12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ipragliflozin: Phase III data

A double-blind, Japanese Phase III trial in 242 Type II diabetics with inadequate glycemic control on a sulfonylurea showed that once-daily 50 mg ipragliflozin an add-on to a sulfonylurea met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo (0.83% vs. a 0.32% increase, p<0.001). Additionally, a greater proportion of patients receiving ipragliflozin achieved a...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >